Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples